Investment Analysts’ Recent Ratings Updates for Allogene Therapeutics (ALLO)

Allogene Therapeutics (NASDAQ: ALLO) has recently received a number of price target changes and ratings updates:

• 11/14/2024 – Allogene Therapeutics had its price target lowered by analysts at Piper Sandler from $11.00 to $9.00. They now have an “overweight” rating on the stock.
• 11/14/2024 – Allogene Therapeutics had its “outperform” rating reaffirmed by analysts at William Blair.
• 11/8/2024 – Allogene Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
• 10/30/2024 – Allogene Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.

Allogene Therapeutics Stock Performance

Allogene Therapeutics stock traded down $0.06 during mid-day trading on Monday, hitting $2.21. 670,197 shares of the company traded hands, compared to its average volume of 2,458,900. Allogene Therapeutics, Inc. has a one year low of $2.01 and a one year high of $5.78. The stock has a fifty day moving average price of $2.75 and a 200-day moving average price of $2.65. The stock has a market cap of $463.37 million, a price-to-earnings ratio of -1.42 and a beta of 0.84.

Institutional Trading of Allogene Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of ALLO. Geode Capital Management LLC boosted its holdings in Allogene Therapeutics by 14.4% in the third quarter. Geode Capital Management LLC now owns 3,227,104 shares of the company’s stock worth $9,037,000 after acquiring an additional 407,070 shares in the last quarter. Barclays PLC raised its holdings in shares of Allogene Therapeutics by 101.5% in the 3rd quarter. Barclays PLC now owns 342,973 shares of the company’s stock valued at $959,000 after buying an additional 172,745 shares during the period. MML Investors Services LLC purchased a new position in shares of Allogene Therapeutics in the 3rd quarter valued at about $56,000. Zacks Investment Management acquired a new stake in Allogene Therapeutics during the 3rd quarter worth approximately $1,446,000. Finally, EP Wealth Advisors LLC raised its holdings in shares of Allogene Therapeutics by 125.6% in the third quarter. EP Wealth Advisors LLC now owns 24,475 shares of the company’s stock worth $69,000 after acquiring an additional 13,625 shares during the last quarter. Hedge funds and other institutional investors own 83.63% of the company’s stock.

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).